Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No VTE Recurrence After 1-Year Follow-Up of Hospitalized Patients With COVID-19 and a VTE Event: A Prospective Study.
Delrue M, Stépanian A, Voicu S, Nassarmadji K, Sène D, Bonnin P, Kevorkian JP, Sellier PO, Molina JM, Neuwirth M, Vodovar D, Mouly S, Mebazaa A, Mégarbane B, Siguret V. Delrue M, et al. Among authors: sellier po. Chest. 2022 Jul;162(1):226-229. doi: 10.1016/j.chest.2022.03.043. Epub 2022 Apr 7. Chest. 2022. PMID: 35398318 Free PMC article. No abstract available.
Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity.
Bastard JP, Fellahi S, Couffignal C, Raffi F, Gras G, Hardel L, Sobel A, Leport C, Fardet L, Capeau J; ANRS CO8 APROCO-COPILOTE Cohort Study Group. Bastard JP, et al. J Antimicrob Chemother. 2015;70(6):1816-24. doi: 10.1093/jac/dkv036. Epub 2015 Mar 1. J Antimicrob Chemother. 2015. PMID: 25733587
Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE).
Avettand-Fenoel V, Bouteloup V, Mélard A, Fagard C, Chaix ML, Leclercq P, Chêne G, Viard JP, Rouzioux C; members of the ETOILE study. Avettand-Fenoel V, et al. J Antimicrob Chemother. 2010 Oct;65(10):2212-4. doi: 10.1093/jac/dkq282. Epub 2010 Jul 28. J Antimicrob Chemother. 2010. PMID: 20667886
Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
Rubenstein E, Diemer M, Goldwirt L, Lascoux-Combe C, Chaix ML, Rami A, Ponscarme D, Lafaurie M, Denis B, De Castro N, Gras J, Liegeon G, Sellier PO, Deville L, Chevret S, Delaugerre C, Molina JM. Rubenstein E, et al. Among authors: sellier po. AIDS. 2024 Jul 1;38(8):1267-1269. doi: 10.1097/QAD.0000000000003887. Epub 2024 May 30. AIDS. 2024. PMID: 38814715
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
Bommenel T, Launay O, Meynard JL, Gilquin J, Katlama C, Lascaux AS, Mahamat A, Martinez V, Pradier C, Rouveix E, Simon A, Costagliola D, Abgrall S; FHDH-ANRS CO4. Bommenel T, et al. J Antimicrob Chemother. 2011 Aug;66(8):1869-77. doi: 10.1093/jac/dkr208. Epub 2011 Jun 1. J Antimicrob Chemother. 2011. PMID: 21636583 Clinical Trial.
Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group. Lortholary O, et al. J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17. J Antimicrob Chemother. 2016. PMID: 26679250
256 results